Why Intra-Cellular Therapies Stock Soared 253% in December
Intra-Cellular Therapies (NASDAQ: ITCI) stock outperformed a booming market last month by jumping 253% compared to a 3% spike in the S&P 500, according to data provided by S&P Global Market Intelligence.
The rally closed an impressive year for shareholders in the biotech stock, which rose 200% for the year to far outpace the market's 29% gain.
Image source: Getty Images.
Source Fool.com
